Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%.
John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii.
Ethan T
ET
Routt
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jacoblevittmd@gmail.com.
Jacob O
JO
Levitt
D000279:Administration, Cutaneous; D000328:Adult; D000068438:Brimonidine Tartrate; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004890:Erythema / Q000139:chemically induced* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D005782:Gels / Q000627:therapeutic use; D006801:Humans; D010146:Pain / Q000139:chemically induced*; D011810:Quinoxalines / Q000009:adverse effects* / Q000627:therapeutic use; D012008:Recurrence; D018570:Risk Assessment; D012393:Rosacea / Q000175:diagnosis / Q000188:drug therapy*; D012494:Sampling Studies; D012720:Severity of Illness Index
D005782:Gels; D011810:Quinoxalines; D000068438:Brimonidine Tartrate